Solu-Moderin 125 mg powder and solvent for solution for injection

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Solu-Moderín 125 mg powder and solvent for injectable solution

methylprednisolone

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor, pharmacist or nurse, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Solu-Moderín 125 mg is and what it is used for
2. What you need to know before using Solu-Moderín 125 mg
3. How to use Solu-Moderín 125 mg
4. Possible side effects
5. How to store Solu-Moderín 125 mg

Contents of the pack and other information

1. What Solu-Moderín 125 mg is and what it is used for

Solu-Moderín 125 mg contains methylprednisolone as the active substance, which belongs to a group of medicines called corticosteroids that work by reducing the production of substances that cause inflammation or allergic reactions.

Solu-Moderín is used in situations requiring immediate corticosteroid treatment, in severe cases or when oral administration is not possible, including:

• Crises due to primary or secondary adrenal insufficiency, shock secondary to adrenocortical insufficiency.
• Anaphylactic shock (severe allergic reaction) and clinical conditions mediated by immediate hypersensitivity mechanisms that may be life-threatening, such as angioedema (generalized urticaria accompanied by swelling of feet, hands, throat, lips, and airways), laryngeal edema (swelling of the throat area due to fluid accumulation).
• For the prevention of anaphylactic shock in accidental poisonings, such as insect stings and snake bites.
• Severe inflammatory respiratory diseases, such as acute exacerbations of bronchial asthma, or in conjunction with appropriate antituberculous chemotherapy for the treatment of fulminant or disseminated tuberculosis.
• As an adjunct to antineoplastic chemotherapy.
• Acute exacerbations of multiple sclerosis (a disease characterized by lesions in the protective membranes of neurons, neurodegenerative and chronic disorders of the central nervous system), cerebral edema (brain inflammation due to fluid accumulation).
• Spinal cord injuries occurring no more than 8 hours previously.

Treatment of acute organ transplant rejection.

2. What you need to know before using Solu-Moderín 125 mg

Do not use Solu-Moderín 125 mg

• if you are allergic to methylprednisolone or any of the other ingredients of this medicine (listed in section 6).
• if you have fungal infections affecting various organs of the body.
• via intrathecal route (injection administered within the membrane covering the brain and spinal cord).
• via epidural route (injection administered around the spinal cord).
• before and after vaccination with live or live attenuated microorganisms if immunosuppressive doses of corticosteroids are to be administered.

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting treatment with Solu-Moderín:

• if you have gastric or duodenal ulcers,

• if you have intestinal diseases due to risk of intestinal perforation with peritonitis, such as non-specific ulcerative colitis with imminent risk of perforation, abscesses or other pyogenic infections, as well as diverticulitis (inflammation of small pouches in the intestinal wall), intestinal anastomosis (surgical reconnection of the intestine), or peptic ulcer,

• if you have any infection, treatment with Solu-Moderín may reduce your resistance to various infections, mask signs of infection, worsen existing infections, or cause reactivation or worsening of old or latent infections. New infections may also occur during treatment with Solu-Moderín. Your doctor will closely monitor you for the development of infections and may consider interrupting treatment or reducing the dose as necessary,

• if you have poliomyelitis (an infectious disease affecting the nervous system), except bulboencephalitic form,

• if you have active tuberculosis, latent tuberculosis, or a positive tuberculin reaction,

• if you are to receive vaccines containing killed or inactivated microorganisms while receiving immunosuppressive doses of corticosteroids, as your response to these vaccines may be reduced.

• if during treatment with Solu-Moderín you may come into contact with individuals infected with diseases such as chickenpox or shingles, even if you do not have symptoms,

• if you have osteoporosis (severe bone demineralization),

• if you have myasthenia gravis, as dose adjustment may be required,

• if you have diabetes, as blood glucose levels may increase,

• if you have congestive heart failure (a condition in which the heart cannot pump oxygen-rich blood effectively),

• if you have simple ocular herpes due to the risk of corneal perforation,

• if during treatment with this medicine you notice any visual disturbances, including vision loss, blurred vision, or other visual changes,

• if you have Cushing's syndrome (rounded face, fat accumulation in the neck area, trunk obesity, etc.), as this medicine may cause or worsen the condition,

• if you have hypothyroidism or hepatic cirrhosis, as dose reduction may be required,

• in case of hyperthyroidism, corticosteroid levels may be reduced,

• if you have hyperactivity of the thyroid gland (hyperthyroidism),

• if symptoms of pancreatitis are detected during treatment,

• if, after intravenous injection of this medicine (usually at an initial dose of ≥ 1 g/day), symptoms of liver injury such as acute hepatitis or elevated liver enzymes are detected, as appropriate monitoring is required in such cases,

• if you have thrombosis or are predisposed to thrombosis,

• if you have hypertension,

• if you have kidney disease,

• if you have scleroderma (also known as systemic sclerosis, an autoimmune disorder), as it may increase the risk of a serious complication called scleroderma renal crisis,

• if you have emotional instability or psychotic tendencies,

• if pheochromocytoma (a rare tumor of adrenal gland tissue) is suspected or has been diagnosed,

• if Solu-Moderín is administered to a premature newborn, cardiac function and structure may need to be monitored.

Tumor lysis syndrome may occur when corticosteroids are used during cancer treatment. Inform your doctor if you have cancer and experience symptoms of tumor lysis syndrome such as muscle cramps, muscle weakness, confusion, irregular heartbeat, vision loss or visual disturbances, and difficulty breathing.

Oral anticoagulants (medicines taken orally to prevent blood clotting), when used together with Solu-Moderín, may increase the risk of bleeding. In some cases, the effect of oral anticoagulants may also be reduced. Your doctor may need to monitor your bleeding risk more frequently through additional blood tests while you are on Solu-Moderín treatment. The dose of Solu-Moderín may also be adjusted if necessary.

Contact your doctor immediately if you experience muscle weakness, muscle pain, cramps, or stiffness while using methylprednisolone. These may be symptoms of a condition called thyrotoxic periodic paralysis, which may occur in patients with hyperactivity of the thyroid gland (hyperthyroidism) treated with methylprednisolone. Additional treatment may be needed to relieve this condition.

Interference with diagnostic tests

If you are scheduled for any diagnostic tests (including blood and urine tests, skin tests using allergens, etc.) during medium or high-dose glucocorticoid therapy, inform your doctor that you are taking this medicine, as it may alter test results.

Use in athletes

If you are subject to doping control tests, note that methylprednisolone may lead to a positive result.

Children and adolescents

Prolonged corticosteroid use has been associated with delayed growth and development in children. Therefore, it should only be used when there are strong medical reasons.

When corticosteroids are used for prolonged periods in infants and children, there is an increased risk of elevated intracranial pressure (increased pressure within the skull).

If high doses of corticosteroids are administered to this population, severe acute pancreatitis may occur.

Other medicines and Solu-Moderín

Inform your doctor or pharmacist if you are currently taking, have recently taken, or might need to take any other medicines.

Dosage adjustments and monitoring for adverse reactions may be necessary. This is especially important if you are taking:

Medicines that may increase methylprednisolone levels: aprepitant, fosaprepitant, cyclosporine, diltiazem, erythromycin, clarithromycin, ethinylestradiol, norethindrone, itraconazole, ketoconazole, troleandomycin, and pharmacokinetic enhancers (cobicistat).

Medicines that may decrease methylprednisolone levels: phenobarbital, phenytoin, primidone, carbamazepine, rifampicin.

Medicines that may increase or decrease methylprednisolone levels: tacrolimus, cyclophosphamide, carbamazepine, aprepitant, fosaprepitant, itraconazole, ketoconazole, diltiazem, ethinylestradiol, norethindrone, erythromycin, clarithromycin, phenobarbital, cyclosporine.

Medicines whose blood levels and/or effects may be affected by methylprednisolone: amphotericin B, xanthines or beta-2 agonists, oral anticoagulants (medicines taken orally to prevent blood clots), anticholinesterases, isoniazid, antidiabetics, non-steroidal anti-inflammatory drugs (NSAIDs), salicylates, anticholinergics (neuromuscular blockers), HIV protease inhibitors, aromatase inhibitors, immunosuppressants, potassium-depleting agents, antihypertensives, toxoids, and vaccines.

Some medicines may enhance the effects of Solu-Moderín, so your doctor may decide to monitor you closely if you are taking medications such as antivirals (ritonavir, indinavir) and pharmacokinetic enhancers (cobicistat), used to treat HIV.

Use of Solu-Moderín with food and drinks

Avoid consuming grapefruit juice, as it may interfere with this medicine.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine, carefully weighing the risks and benefits.

Pregnancy

This medicine may be used during pregnancy only if considered necessary by your doctor.

Infants born to mothers who received high doses of corticosteroids during pregnancy should be closely monitored for possible signs of adrenal insufficiency. Cataracts have been reported in infants born to mothers who received prolonged corticosteroid therapy during pregnancy.

The risk of low birth weight is dose-related and can be minimized by using low doses of corticosteroids.

Breastfeeding

Solu-Moderín passes into breast milk.

Driving and use of machines

Treatment with corticosteroids may cause dizziness, vertigo, visual disturbances, and fatigue.

Therefore, do not drive or operate machinery if you experience these effects during treatment with Solu-Moderín.

Solu-Moderín 125 mg contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per vial; hence, it is essentially “sodium-free”.

3. How to use Solu-Moderín 125 mg

Follow exactly the administration instructions for this medicine as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Solu-Moderín may be administered intravenously (by injection or infusion) or intramuscularly (by injection).

The intravenous route is the preferred route of administration in cases of shock or other acute conditions.

The intravenous line used for methylprednisolone administration must not be used for administering any other drug. A separate intravenous line should be used for infusion, distinct from the one used for bolus injection.

The dose will be individualized for each patient and may be adjusted depending on the severity of the condition and the patient's response. The lowest effective dose necessary to control the disease should be used, and treatment should be continued for the shortest possible duration.

It should also be determined whether administration will be daily or intermittent.

Dose reduction should be gradual, particularly after relatively high doses.

Your doctor will decide when to switch to oral therapy.

In life-threatening situations, treatment should be initiated with doses of 250 mg to 1,000 mg of methylprednisolone.

• Adrenal insufficiency: 16 to 32 mg by intravenous infusion, followed by an additional 16 mg over 24 hours.

In these crises and in Waterhouse-Friderichsen syndrome, simultaneous administration of mineralocorticoids is indicated.

• Anaphylactic shock and conditions mediated by immediate hypersensitivity mechanisms: 250 mg to 500 mg of methylprednisolone.

• Severe inflammatory respiratory diseases: 30 to 90 mg/day.

In status asthmaticus, 250 to 500 mg of methylprednisolone is recommended.

• Acute relapses of multiple sclerosis: administer 500 mg/day or 1 g/day for 3 or 5 days by intravenous injection.

• Cerebral edema: 250 to 500 mg of methylprednisolone.

• Acute spinal cord injury: 30 mg of methylprednisolone per kg of body weight as an IV bolus dose administered over a minimum of 15 minutes. After a 45-minute pause, a continuous intravenous infusion of 5.4 mg/kg/hour should be administered for 23 hours for patients in whom treatment was initiated within 3 hours of injury, and for 47 hours for those in whom treatment was initiated between 3 and 8 hours after injury.

• Rejection crises: up to 30 mg/kg body weight.

Use in children and adolescents

The dose should be based on the severity of the disease and the patient's response, rather than on age or body weight.

In any case, the pediatric dose should not be less than 0.5 mg/kg every 24 hours.

In life-threatening situations, treatment should be initiated with single doses of 4 to 20 mg/kg body weight in children.

If you use more Solu-Moderín than you should

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medicine and the amount ingested.

If you forget to use Solu-Moderín

Do not use a double dose to make up for missed doses.

If you stop treatment with Solu-Moderín

Do not stop using this medicine without consulting your doctor.

If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

The following reactions have been reported with the following contraindicated routes of administration: intrathecal/epidural: arachnoiditis, functional gastrointestinal disorders/vesical dysfunction, headache, meningitis, paraparesis/paraplegia, epileptic seizures, sensory disturbances.

The reported adverse effects are classified according to their frequency as follows: frequent adverse effects (may affect up to 1 in 10 people) and frequency not known (cannot be estimated from the available data).

Infections and infestations

Frequent: infection.

Frequency not known: opportunistic infection, peritonitis (may be the first sign or symptom present in a gastrointestinal disorder such as perforation, obstruction, or pancreatitis).

Disorders of the blood and lymphatic system

Frequency not known: elevated white blood cell count (leukocytosis).

Immune system disorders

Frequency not known: drug hypersensitivity, anaphylactic reaction, anaphylactoid reaction.

Endocrine disorders

Frequent: Cushingoid.

Frequency not known: hypothalamic-pituitary-adrenal axis suppression, steroid withdrawal syndrome.

Metabolism and nutrition disorders

Frequent: sodium retention, fluid retention.

Frequency not known: metabolic acidosis, epidural lipomatosis, hypokalemic alkalosis, dyslipidemia, decreased glucose tolerance, increased insulin requirement (or increased need for oral hypoglycemics in diabetics), accumulation of adipose tissue in localized areas of the body (lipomatosis), increased appetite (which may lead to weight gain).

Psychiatric disorders

Frequent: affective disorder (including depressed mood, euphoric mood).

Frequency not known: affective disorder (including affective lability, drug dependence, suicidal ideation), psychotic disorder (including mania, delusional disorder, hallucination, and schizophrenia), mental disorder, personality change, confusional state, anxiety, mood changes, abnormal behavior, insomnia, irritability.

Nervous system disorders

Frequency not known: increased intracranial pressure (with papilledema [benign intracranial hypertension]), epileptic seizures, amnesia, cognitive disorder, dizziness, headache.

Eye disorders

Frequent: cataract.

Frequency not known: disease of the retina and choroid membrane (chorioretinopathy), glaucoma, exophthalmos, blurred vision.

Ear and labyrinth disorders

Frequency not known: vertigo.

Cardiac disorders

Frequency not known: congestive heart failure (in susceptible patients), arrhythmia.

Vascular disorders

Frequent: hypertension.

Frequency not known: blood clots (thrombotic events), hypotension, warmth and redness of the skin (rubefaction).

Respiratory, thoracic and mediastinal disorders

Frequency not known: pulmonary embolism, hiccups.

Gastrointestinal disorders

Frequent: peptic ulcer (with possible perforation and hemorrhage).

Frequency not known: intestinal perforation, gastric bleeding, pancreatitis, ulcerative esophagitis, esophagitis, abdominal distension, abdominal pain, diarrhea, dyspepsia, nausea.

Hepatobiliary disorders

Frequency not known: methylprednisolone may harm your liver; cases of hepatitis and increased liver enzymes have been reported.

Skin and subcutaneous tissue disorders

Frequent: bruising, skin atrophy, acne.

Frequency not known: angioedema, hirsutism, petechiae, erythema, hyperhidrosis, striae of the skin, rash, pruritus, urticaria, hypopigmentation of the skin, inflammation of the fatty tissue under the skin, which may cause the skin to feel hard and painful red lumps or patches to appear (panniculitis), which has been reported after dose reduction or discontinuation of prolonged treatment. Most cases resolve spontaneously.

Musculoskeletal and connective tissue disorders

Frequent: muscle weakness, osteoporosis, growth retardation.

Frequency not known: myalgia, myopathy, muscle atrophy, osteonecrosis, pathological fracture, neuropathic arthropathy, arthralgia.

Reproductive system and breast disorders

Frequency not known: irregular menstruation.

General disorders and administration site conditions

Frequent: impaired healing.

Frequency not known: peripheral edema, fatigue, malaise, injection site reaction.

Investigations

Frequent: decreased blood potassium.

Frequency not known: increased intraocular pressure, decreased carbohydrate tolerance, elevated urinary calcium, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), increased alkaline phosphatase (ALP) in blood, elevated blood urea.

Injury, poisoning and procedural complications

Frequency not known: vertebral compression fracture, tendon rupture (especially of the Achilles tendon).

Other adverse effects in children

The following reactions were more frequent in children: mood changes, abnormal behavior, insomnia, irritability.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist or nurse, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Solu-Moderín 125 mg

No special storage conditions are required.

Shelf life after reconstitution: 48 hours.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month indicated.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused containers and medicines at the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the container and other information

Composition of Solu-Moderín 125 mg powder and solvent for injectable solution

• The active substance is methylprednisolone (sodium succinate). Each vial of powder contains 125 mg of methylprednisolone (as sodium succinate).
• The other components (excipients) are: monobasic sodium phosphate monohydrate, dibasic anhydrous sodium phosphate, and water for injections.

Appearance of the product and contents of the container

Solu-Moderín 125 mg is presented as powder and solvent for injectable solution.

Lyophilized white powder in a vial and clear, colorless solvent in an ampoule.

Solu-Moderín 125 mg is packaged in containers of 1 vial with powder and 1 ampoule with solvent, 3 vials with powder and 3 ampoules with solvent, 50 vials with powder and 50 ampoules with solvent.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder

Pfizer, S.L.

Avda. de Europa, 20-B. Parque Empresarial La Moraleja - 28108 Alcobendas (Madrid)

Manufacturer

Valdepharm

Parc Industriel d’Incarville, BP 606

27106 Val de Reuil Cedex. France

Date of the most recent review of this summary: December 2025

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.

---

This information is intended for healthcare professionals only:

Solu-Moderin must be reconstituted before use. Aseptic technique is required for its preparation.

• Reconstitution of the injection solution:

The powder contained in the vial should be reconstituted with the solvent provided in the ampoule.

Shake well until a clear solution is obtained.

• Reconstitution of the infusion solution:

First, reconstitute the powder in the vial as previously indicated. The reconstituted solution may be administered in diluted solutions of 5% dextrose in water, isotonic saline, or 5% dextrose in 0.45% or 0.9% sodium chloride.